BioAscent has announced that it will be exhibiting at the 17th Discovery on Target conference being held in Boston on the 16th – 19th September.
This conference will focus on targeting GPCRs for Drug Discovery, Small Molecule Drug Discovery and Practical Phenotypic Screening, and is set to attract over 1300 drug discovery professionals.
BioAscent’s Chief Commercial Officer, Dr Mike Piper will be joining the recently appointed Director of Business Development for North America, Julian Abery.
BioAscent will also be presenting a poster on a study that describes the follow up to a screening campaign conducted for the European Lead Factory (ELF) against a mitochondrial enzyme which is linked to the proliferation and tumorigenic capacity of some cancer types. The poster is entitled ‘Thermal shift indicates that oxalic acid is a prevalent contaminant of hits identified by high throughput screening.’
For more information, click here.